Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
77
NVSEF Quote, Financials, Valuation and Earnings
Last price:
$97.80
Seasonality move
:
-2.92%
Day range:
$97.80 - $97.80
52-week range:
$90.24 - $123.55
Dividend yield:
3.83%
P/E ratio:
11.47x
P/S ratio:
4.02x
P/B ratio:
4.51x
Volume:
155
Avg. volume:
43.1K
1-year change:
-1.01%
Market cap:
$195.5B
Revenue:
$46.7B
EPS (TTM):
$8.53
Analysts' Opinion
-
Consensus RatingNovartis AG has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Novartis AG has an estimated downside of -15.13% from its current price of $97.80.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $97.80.
Fair Value
-
According to the consensus of 0 analysts, Novartis AG has -15.13% downside to fair value with a price target of -- per share.
NVSEF vs. S&P 500
-
Over the past 5 trading days, Novartis AG has underperformed the S&P 500 by -2.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novartis AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novartis AG has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Novartis AG reported revenues of $13.2B.
Earnings Growth
-
Novartis AG has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Novartis AG reported earnings per share of $1.57.
Enterprise value:
212B
EV / Invested capital:
2.87x
Price / LTM sales:
4.02x
EV / EBIT:
15.49x
EV / Revenue:
4.24x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
16.95x
Price / Operating cash flow:
16.04x
Enterprise value / EBITDA:
10.75x
Gross Profit (TTM):
$37.4B
Return On Assets:
17.33%
Net Income Margin (TTM):
35.25%
Return On Equity:
41.89%
Return On Invested Capital:
25.8%
Operating Margin:
27.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $41.3B | $45.9B | $49.9B | $12.1B | $13.2B | |
| Gross Profit | $31B | $33.4B | $37.4B | $9B | $9.9B | |
| Operating Income | $7.8B | $8.9B | $13.6B | $1.8B | $3.6B | |
| EBITDA | $28.6B | $17.7B | $19.7B | $4.9B | $5.6B | |
| Diluted EPS | $9.72 | $3.72 | $8.53 | $0.85 | $1.57 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29B | $26.3B | $37B | $45.7B | $31.3B | |
| Total Assets | $129.7B | $121.2B | $118.5B | $112.7B | $103.5B | |
| Current Liabilities | $31.8B | $29.9B | $28.2B | $48.4B | $28.1B | |
| Total Liabilities | $75.1B | $64.3B | $57.6B | $74.5B | $60.1B | |
| Total Equity | $54.6B | $56.9B | $60.9B | $38.2B | $43.4B | |
| Total Debt | $36.2B | $32.4B | $26.8B | $23.5B | $30.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14B | $16B | $16B | $5.4B | $6.3B | |
| Cash From Investing | $7.5B | $5.9B | -$6.2B | -$2.2B | -$374M | |
| Cash From Financing | -$19.8B | -$17.7B | -$9.4B | -$832M | -$382M | |
| Free Cash Flow | $11.7B | $13.6B | $12.5B | $4.7B | $5.5B | |
NVSEF
Sector
Market Cap
$195.5B
$46.1M
Price % of 52-Week High
79.16%
46.02%
Dividend Yield
3.83%
0%
Shareholder Yield
6.14%
-0.6%
1-Year Price Total Return
-1.01%
-30.52%
Beta (5-Year)
0.569
0.772
Dividend yield:
3.83%
Annualized payout:
$3.40
Payout ratio:
43.31%
Growth streak:
3 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$96.95
200-day SMA
Sell
Level
$104.49
Bollinger Bands (100)
Sell
Level
102.2 - 115.02
Chaikin Money Flow
Sell
Level
-20.4M
20-day SMA
Sell
Level
$99.48
Relative Strength Index (RSI14)
Sell
Level
44.13
ADX Line
Buy
Level
16.03
Williams %R
Neutral
Level
-62.0589
50-day SMA
Sell
Level
$104.01
MACD (12, 26)
Sell
Level
-2.23
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-7.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.06)
Buy
Beneish M-Score
(Annual)
Level (-2.8929)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-2.1989)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Stock Forecast FAQ
In the current month, NVSEF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVSEF average analyst price target in the past 3 months is --.
-
Where Will Novartis AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novartis AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novartis AG?
Analysts are divided on their view about Novartis AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novartis AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Novartis AG's Price Target?
The price target for Novartis AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVSEF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novartis AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVSEF?
You can purchase shares of Novartis AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novartis AG shares.
-
What Is The Novartis AG Share Price Today?
Novartis AG was last trading at $97.80 per share. This represents the most recent stock quote for Novartis AG. Yesterday, Novartis AG closed at $97.80 per share.
-
How To Buy Novartis AG Stock Online?
In order to purchase Novartis AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
